Evidence map›Paper›PMID 40873076›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Introduction of the key update points of the 2025 Canadian Association for the Study of the Liver guideline for the management of chronic hepatitis B].

H Zhuang

Abstract readEnglish Abstract
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

H ZhuangPeking University Health Science Center, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada developed jointly the 2025 guidelines for the management of chronic hepatitis B in May 2025. The guidelines updated recommendations for universal adult HBV screening, vaccination, laboratory assessment, treatment, patient-centered care, early diagnosis, expanding antiviral treatment. Notably, the guidelines recommend reflex HDV testing and routine use of quantitative HBsAg for the decision of HBV management.

Indexed as

Hepatitis B, ChronicAntiviral AgentsCanadaHepatitis B Surface AntigensHumansPractice Guidelines as TopicAntiviral AgentsHepatitis B Surface Antigens

Identifiers

PMID40873076
PMCPMC12861775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.